Furthermore, multiple reports have been made of a minority fraction of infection that persists despite targeting of SR-B1 with CRISPR, siRNA or antibody blockade [39,41,47,48], supporting the notion of an SR-B1-independent mode of entry. This evidence concerns the gene SCARB1 and infection.